This study was the answer to a recent quiz solved by ‘julescat’ (#msg-44002107, #msg-44000662). It’s the only HCV study (as far as I know) where two oral agents—of which neither has completed even a phase-2a study—are being combined in a regimen that does not include interferon or ribavirin.
New quiz question: What other consequential feature of this trial is a first in the HCV arena?